Posts by acn:

Sentire思騰(R)腔鏡手術機械人獲歐盟CE與新加坡HSA雙認證, 康諾思騰(Cornerstone Robotics)全球化戰略全面提速

香港, 2026年5月26日 - (亞太商訊 via SeaPRwire.com) - 香港創新型手術機械人企業康諾思騰(Cornerstone Robotics)欣然宣布,其自主研發的 Sentire思騰(R)腔鏡手術機械人,成功獲得歐盟《醫療器械法規》(CE MDR)權威認證,並同步取得新加坡衞生科學局(HSA)認證,兩項認證均涵蓋泌尿外科、普通外科、婦科及胸外科等微創手術領域。這次雙里程碑式的突破,標誌著Sentire思騰(R)正式獲准進入歐洲與亞太地區的核心醫療市場。康諾思騰亦成為首個同步完成歐盟法規認證與深度歐洲臨床驗證的香港手術機械人品牌,彰顯本港自主研發的高品質醫療器械已進駐國際市場主賽道。 首個香港品牌完成歐盟法規與臨床雙認證Sentire思騰(R)手術機械人深度融合了臨床醫學、精密工程、前沿軟件及超高清影像技術,屬頂尖的高端醫療系統平台。此次成功獲得歐盟CE認證,不僅證明了其安全性、臨床有效性及質量管理等關鍵領域,已全面達到國際主流的合規標準,更標誌著這項高品質自主研發平台,已具備全方位服務全球醫患的卓越實力與專業資格。公司早前於英國倫敦和樸次茅斯設立分支機構,並依託全球三大研發中心的協同體系,持續吸納歐洲頂尖科研人才與豐富臨床資源,為產品技術升級與臨床適用度注入國際化創新動能。自2025年起,康諾思騰攜手英國樸次茅斯大學醫院NHS基金信托(Portsmouth Hospitals University,PHU)啟動Sentire思騰(R)的臨床評估項目,持續累積歐洲真實臨床數據,為循證研究、系統化培訓及臨床應用推廣提供堅實支持。截至目前,Sentire思騰(R)已在英國成功完成涵蓋泌尿外科、胃腸外科、婦科等核心科室的複雜手術临床试验,其在應對各類手術環境時的卓越穩定性與廣泛適用性,獲得海外臨床專家高度肯定與此同時,新加坡衞生科學局(HSA)認證於亞太區享有極高國際公信力,向來引領全球主流醫療安全與成效的標準。Sentire思騰(R)此次同步獲得歐盟與新加坡雙重權威認證,充分彰顯其在全球不同監管體系下的卓越實力,亦印證了這項本港自主研發技術的成熟度,高品質水平廣受國際醫療界肯定。深耕全球市場,打造一站式本地化服務秉承「立足香港,放眼全球」的戰略視野,康諾思騰在香港投資管理有限公司(港投公司)的戰略注資支持下,正積極深化全球本地化佈局,以專業深度賦能全球醫患。在歐洲市場,公司於2025年正式成立英國子公司,積極構建涵蓋售前專業培訓、臨床技術支援、以及售後保障的全週期一站式本地化服務體系。康諾思騰已在英國順利開展多場系統化培訓,對象涵蓋外科醫生、手術室護理團隊及醫院技術支援人員,全力推動臨床團隊迅速掌握操作系統的熟練度並建立使用信心,為後續的規模化商業推廣構築穩固基石。在持續深化歐洲佈局的同時,康諾思騰亦積極拓展亞太區內合作網絡。公司早前與新加坡國立健保集團(NHG)及南洋理工大學李光前醫學院(LKC Medicine)正式簽署三方戰略合作備忘錄,共同推進新加坡醫療創新生態體系建設;並於2026年4月,於NHG旗下的兀蘭醫院(Woodlands Hospital)成功設置當地首台Sentire思騰(R),正式進駐新加坡醫療系統。作為進駐當地的首台系統,Sentire思騰(R) 將面向當地多家醫院的外科團隊開放,全面賦能前線醫護進行系統化操作培訓與臨床流程適配,在科研與教學場景中率先發揮卓越效能,穩步推動手術機械人創新應用在新加坡長遠發展。全自主研發與垂直整合 構築引領國際市場的技術根基康諾思騰始終堅持全方位自主研發與垂直整合的長期戰略,成功搭建覆蓋機械、電機、軟件、算法,以及視覺影像技術等核心技術的全面底層技術平台。高度的技術自主可控,不僅帶來了卓越的臨床表現,確保了供應鏈的自主性與高度穩定,亦大幅提升了未來科研創新的敏捷度與戰略高度。基於全自主研發與垂直整合所構築的高品質技術系統,讓Sentire思騰(R)在各類複雜手術中,均能展現出色的穩定性與精準可控的表現。康諾思騰創始人兼首席執行官歐國威教授表示:「榮獲歐盟CE及新加坡HSA認證,是康諾思騰從技術深耕邁向全球臨床應用的重要里程碑。從在英國樸次茅斯開展首次臨床驗證,到如今順利取得多個關鍵區域的市場批准,每一步都凝聚著團隊對自主創新與臨床價值的執着。我們堅信,在競爭激烈的國際市場中,贏得長期信賴的核心在於卓越的產品品質與紮實的臨床表現。未來,我們將持續深耕全球核心醫療市場,依託專業的本地化團隊與一站式服務體系,並與全球頂尖醫療機構攜手,為更多醫患提供高品質的手術機械人解決方案。」這項雙重認證的落地,不僅是Sentire思騰(R)奠定進入歐洲及亞太市場的重要起點,更標誌著康諾思騰全球化計劃進入加速階段。而資本層面的戰略支持亦為康諾思騰全球化佈局注入強勁動能。2025年11月,康諾思騰完成約2億美元超募融資,由港投公司領投,並獲全球戰略投資者與全球頂級主權基金共同參與。港投公司作為香港特區政府全資擁有的「耐心資本」投資機構,其注資彰顯市場對公司全球商業化實力與長遠發展前景的信心,同時體現特區政府對本地創新科技企業的肯定與堅實支持,為公司拓展歐洲及亞太市場提供雄厚資源保障。立足於堅實的技術基礎與充裕資源,公司將持續推動Sentire思騰(R)的臨床應用拓展與技術優化,並以歐洲及亞太市場為戰略支點,逐步構建覆蓋全球的國際創新協作網絡,為全球外科醫生提供更精準可靠的手術機械人解決方案,為全球患者帶來更高質量的生命守護。關於康諾思騰(Cornerstone Robotics)康諾思騰(Cornerstone Robotics)是於中國香港成立並完成孵化的創新型手術機械人企業,懷著「引領醫療創新,心繫天下健康」的願景,致力於打造安全高效的手術機械人平台,提升全球範圍優質醫療資源的可及性,讓更多患者受益於高端醫療科技帶來的高品質醫療服務。公司已在全球設立三大研發中心,並在中國香港、深圳、北京、上海、英國倫敦和樸次茅斯等地設有分支機構,在粵港澳大灣區建成30,000平米的量產工廠。憑藉雄厚的技術實力,公司已成功攻克技術難題,搭建起全面底層技術平台,由康諾思騰自主研發的Sentire思騰(R)腔鏡手術機械人已完成多個重要專科的臨床試驗,並在中國、歐盟、新加坡等多個國家與地區獲批上市,服務全球醫護,惠及更多病患。如欲瞭解更多,可瀏覽:https://www.csrbtx.com  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Sentire(R) Surgical System Receives EU CE Mark (MDR) and Singapore HSA Approval, Cornerstone Robotics Accelerates Global Strategic Expansion

HONG KONG, May 26, 2026 - (ACN Newswire via SeaPRwire.com) - Cornerstone Robotics, a leading innovator in surgical robotics based in Hong Kong, is pleased to announce that its proprietary Sentire(R) Surgical System has officially received European Union CE mark certification under the Medical Device Regulation (MDR) and has simultaneously obtained approval from the Health Sciences Authority (HSA) of Singapore. These certifications cover minimally invasive surgical procedures in General Surgery, Gynecology, Thoracic and Urology. This milestone marks the formal entry of the Sentire(R) Surgical System into the core medical markets of Europe and the Asia-Pacific. Cornerstone Robotics has thus become the first Hong Kong-based surgical robotics brand to simultaneously complete EU regulatory certification and in-depth European clinical validation, signaling that Hong Kong’s high-quality medical device innovation has officially entered the international market’s main track. Achieving Combined Regulatory Approval and Clinical ValidationThe Sentire(R) Surgical System is a high-end surgical robotic platform that combines clinical workflows with integrated engineering, software, and imaging technologies. Achieving CE certification not only demonstrates that its safety, efficacy, and quality management system fully comply with stringent international regulatory standards but also affirms that this high-quality platform possesses the robust capability and credentials to serve physicians and patients worldwide.Alongside regulatory certification, Cornerstone Robotics has simultaneously advanced its international clinical validation. By leveraging its three global R&D centres and establishing an early presence in the UK, the Company has integrated European talent and clinical resources to inject international innovation momentum into product iteration and clinical adaptation. Since 2025, the Company has partnered with Portsmouth Hospitals University NHS Trust (PHU) to undertake a fully compliant clinical investigation for the Sentire(R) Surgical System, steadily accumulating real-world European clinical data to support evidence-based research, training protocol development, and clinical adoption. To date, the Sentire(R) Surgical System has successfully completed numerous complex procedures in the UK, spanning core specialties including urology, gynecology, and upper and lower gastrointestinal surgery. The investigation achieved positive patient outcomes, and the clinicians were very satisfied with the system’s performance.   Concurrently, the Singapore HSA certification, as one of the highly mature and internationally recognised medical device market access systems in the Asia-Pacific, is similarly renowned for its rigorous safety and efficacy evaluations. The Sentire(R) Surgical System's simultaneous achievement of certifications from both the EU and Singapore fully demonstrates Cornerstone Robotics' quality and compliance across different global regulatory frameworks.Deepening Global Presence with One-Stop Localised ServicesAdhering to its “From Hong Kong to the World” strategy, Cornerstone Robotics has deepened its global localisation efforts with the strategic support of the Hong Kong Investment Corporation (the HKIC), aiming to empower physicians and patients worldwide through professional service. In the European market, to further support regional customers and enhance clinical responsiveness, the Company established its UK subsidiary in 2025, initiating a one-stop service provision encompassing professional training, clinical technical support, and after-sales service. The Company has already completed multiple training sessions in the UK, covering surgeons, operating room nursing teams, and hospital technical support personnel, helping clinical teams rapidly build proficiency and confidence in operating the Sentire(R) Surgical System, thereby establishing a solid foundation for scaled commercial rollout.While continuing to deepen its European footprint, Cornerstone Robotics has also been actively expanding its Asia-Pacific collaboration network. Previously, Cornerstone Robotics signed a tripartite Memorandum of Understanding (MOU) with the National Healthcare Group (NHG) and the Lee Kong Chian School of Medicine (LKC Medicine) of Nanyang Technological University, Singapore, to jointly advance the development of Singapore's healthcare innovation ecosystem. In April 2026, Cornerstone Robotics completed the first installation of the Sentire(R) Surgical System in Singapore at Woodlands Hospital under NHG. The system is being made available to surgical teams from multiple local hospitals for system testing, operation training and clinical workflow adaptation assessments. This deployment leverages the system’s performance in research and training, steadily advancing the adoption of innovative surgical robotic applications in Singapore and the broader Asia-Pacific region.Full-Stack In-House R&D and Vertical Integration: The Foundation for High-Quality Global ExpansionCornerstone Robotics has consistently adhered to the long-term strategy of full-stack in-house R&D and vertical integration, which forms the foundation of its competitive advantage and high-quality international expansion. Anchored in this strategy, the Company has successfully built an underlying technology platform spanning mechanical, electrical, software, algorithmic, and vision imaging technologies. This high degree of technological autonomy ensures superior clinical performance, secures supply chain resilience, and enhances the agility and long-term innovation potential of its R&D. Built upon this vertically integrated architecture, the Sentire(R) Surgical System delivers exceptional stability and predictable performance in demanding surgical environments.Professor Samuel Au, Founder and CEO of Cornerstone Robotics, commented: “Receiving both EU CE and Singapore HSA certifications marks a major milestone in Cornerstone Robotics' evolution from technology innovator to a global clinical solution provider. From our first clinical investigation in Portsmouth, UK, to formally securing multi-jurisdictional regulatory approvals, every step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring advanced surgical robotic solutions to more physicians and patients worldwide.”The successive approvals of both EU CE and Singapore HSA certifications represent not only important market access gateways for the Sentire(R) Surgical System, but also a signal that Cornerstone Robotics' globalisation strategy has entered an accelerated phase. Strategic capital support has injected further momentum into this global push. In November 2025, Cornerstone Robotics successfully completed an oversubscribed financing round of approximately US$200 million, led by the HKIC with participation of global strategic investors and top-tier sovereign funds. As a flagship “patient capital” investor wholly owned by the HKSAR Government, the HKIC’s investment underscores market confidence in Cornerstone Robotics' global commercial capabilities and long-term growth prospects. With the European and Asia-Pacific markets as strategic anchors, Cornerstone Robotics is delivering more precise and reliable robotic solutions to physicians worldwide and extending higher-quality life protection to patients across the globe.About Cornerstone Robotics (CSR)Established and incubated in Hong Kong, Cornerstone Robotics (CSR) is an innovative surgical robotics unicorn driven by the vision of leading medical innovations for a healthier world. It advances surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centers worldwide, the company has established a 30,000-square-meter manufacturing facility in China. Developed entirely in-house, its Sentire(R) surgical system has successfully completed multi-specialty clinical trials and received market approval in multiple countries and regions, including China, the European Union and Singapore, serving medical professionals globally and bringing better care to more patients.To find out more information, please visit our website at https://en.csrbtx.com/   Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

How to Manage Large Purchases During Sale Season Responsibly

SINGAPORE, May 25, 2026 - (ACN Newswire via SeaPRwire.com) - Sale seasons in Singapore, such as the Great Singapore Sale or the year-end 12.12 events, offer significant opportunities to save on high-ticket items. However, the pressure of flash deals and limited-time offers can easily lead to impulsive overspending. Managing these large purchases responsibly requires disciplined planning and using financial tools like quick loans to maintain your long-term stability.Selecting a flexible credit line or quick loans may provide access to funds that can be considered as part of managing expenses during sale periods. This approach may help you with short-term cash flow management while meeting daily expenses. The following strategies focus on how to navigate major sale events while keeping your financial health intact.Create a prioritised shopping listBefore the sales begin, you should identify what you truly need versus what you simply want. A common mistake is falling into the trap of discount illusion, where buying a discounted item you do not actually need is viewed as a saving when in reality, it is an unnecessary expense.List your intended large-scale purchases in a spreadsheet, noting their original prices and the stores that sell them. Prioritise these items based on their utility and longevity, such as essential home appliances or quality electronics. This preparation allows you to act decisively on genuine deals while ignoring filler items that only serve to drain your budget.Set a hard budget capThe excitement of a sale can often cloud your financial judgment, leading to multiple impulsive purchases, thus making you lose track of your total expenses. To avoid this, determine a realistic total amount you are willing to spend across the entire sale season.If your high-priority items exceed your current cash in hand, you might consider using quick loans to bridge the gap. A flexible credit line can offer immediate access to funds, but you must ensure the total loan amount fits within your calculated repayment capacity. Establishing this limit early may help you not to fall short of funds for the remainder of the month due to a single weekend of shopping.Use flexible financing to control cash flowLarge purchases often require significant upfront cash that can temporarily destabilise your monthly balance. In such cases, quick loans or a personal line of credit can serve as a valuable tool for managing short-term cash flow.Some credit lines may offer promotional interest rates of up to 0% interest for several months, subject to applicable terms and conditions. This flexibility allows you to secure the sale price of a large item immediately while spreading the cost over a few months. Repaying the balance quickly may help you benefit from the sale discount without losing those savings to interest charges.Think twice before you payFlash sales and discount banners are designed to trigger a fear of missing out, thus forcing you to act in haste. One of the effective ways to counteract this is the 24-hour rule: wait a full day before proceeding to purchase any non-essential large item.Giving yourself this time allows the initial emotional impulse to fade, helping you decide if the item truly adds value to your life. If the deal is still available and fits your budget the next day, you can proceed with confidence. This simple pause can save you a lot of funds and from buyer's remorse in the foreseeable future.Focus on quality and long-term valueA low price tag does not always equal a good deal if the product requires frequent repairs or expensive maintenance. When shopping for large items during a sale, prioritise quality over quantity by researching product reviews and warranties.Investing in a durable, high-quality appliance, even at a slightly higher sale price, often costs less in the long run than a cheaper, lower-quality alternative. Additionally, always check return policies before purchasing, as being stuck with a non-returnable faulty item can turn a temporary bargain into a long-term loss.Final thoughtsManaging large purchases during Singapore's sale seasons is about making informed decisions that align with your financial goals. By using a structured plan and leveraging tools like quick loans responsibly, you can enjoy the full benefits of a sale without lingering financial distress.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB Ltd.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

宇樹科技IPO上會在即 首程控股(697.HK)機器人資產迎估值重估

香港, 2026年5月26日 - (亞太商訊 via SeaPRwire.com) - 首程控股(697.HK)在機器人產業鏈的前瞻布局,正迎來新的估值催化。5月25日,上交所官網顯示,上海證券交易所上市審核委員會定於2026年6月1日召開2026年第31次審議會議,審議宇樹科技股份有限公司科創板首發上市申請。作為國內具身智能與人形機器人領域的代表性企業,宇樹科技IPO進程穩步推進,有望提升機器人產業鏈在資本市場的關注度,也將為首程控股相關機器人資產提供更清晰的估值參照。公開資料顯示,宇樹科技科創板IPO申請已於今年3月20日獲上交所受理,擬募集資金42.02億元。按新股發行不低於發行後總股本10%測算,宇樹科技對應整體發行估值不低於420億元人民幣。首程控股通過北京機器人產業發展投資基金參與宇樹科技投資,該基金在宇樹科技發行前持股3.8262%,發行後持股比例約3.44%。按上述估值測算,該部分股權對應價值約14.46億元人民幣。對首程控股而言,宇樹科技上會意味著其機器人產業投資進入價值驗證階段。近年來,公司圍繞具身智能、服務機器人及商業化應用場景持續布局,逐步構建「產業基金投資+線下場景落地+資本化退出」的綜合模式。若宇樹科技順利上市,將有助於提升首程控股機器人資產的可視化估值,並增強市場對其產業投資能力的認可。整體來看,宇樹科技IPO為首程控股打開產業催化與估值重估窗口,公司中長期估值彈性有望進一步釋放。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Unitree Robotics IPO Review Approaches, Shoucheng Holdings Robot Assets Poised for Valuation Re-rating

HONG KONG, May 26, 2026 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings (697.HK) is seeing a new valuation catalyst from its forward-looking deployment across the robotics industry chain. On May 25, information on the Shanghai Stock Exchange website showed that the SSE Listing Review Committee is scheduled to hold its 31st review meeting of 2026 on June 1, 2026, to review the STAR Market IPO application of Unitree Robotics Co., Ltd. As a representative company in China’s embodied intelligence and humanoid robotics sectors, Unitree Robotics’ steady IPO progress is expected to raise capital-market attention toward the robotics value chain and provide a clearer valuation reference for Shoucheng’s related robotics assets.Public information shows that Unitree Robotics’ STAR Market IPO application was accepted by the SSE on March 20 this year, with planned fundraising of RMB4.202 billion. Based on the assumption that the new shares will account for no less than 10% of the post-issue share capital, Unitree Robotics would have an implied post-issue valuation of no less than RMB42.0 billion. Shoucheng Holdings participates in the investment in Unitree Robotics through the Beijing Robotics Industry Development Investment Fund. The fund held 3.8262% of Unitree Robotics before the offering and is expected to hold approximately 3.44% after the offering. Based on the above valuation estimate, the corresponding value of this equity stake would be about RMB1.446 billion.For Shoucheng Holdings, Unitree Robotics’ upcoming review means that its robotics industry investment is entering a value-validation stage. In recent years, the company has continued to deploy capital and resources in embodied intelligence, service robots and commercial application scenarios, gradually building an integrated model of industrial fund investment, offline scenario implementation and capital-market exits. If Unitree Robotics is successfully listed, it will help enhance the visible valuation of Shoucheng’s robotics assets and strengthen market recognition of its industrial investment capabilities. Overall, Unitree Robotics’ IPO creates a clear industrial catalyst and valuation re-rating window for Shoucheng, with the company’s medium- to long-term valuation upside expected to be further unlocked. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Patents Build Solid Barriers, Technologies Achieve All-Round Breakthroughs, New Vision Leads the New Track of AR Interaction

HONG KONG, May 22, 2026 - (ACN Newswire via SeaPRwire.com) - Patents are the key assets of technology enterprises, a solid moat for defending against market competition, and an important yardstick for measuring an enterprise's technical strength and seizing market dominance. At a time when the intelligent vehicle industry is accelerating iteration and intelligent cockpit interaction experience has become a core decision-making factor for users, HUD, as the core interactive terminal of intelligent cockpits, has become a key track for automakers' differentiated competition. The depth, breadth and accuracy of patent layout directly determine an enterprise's position and long-term development ceiling in the industry.As the first Hong Kong-listed stock in AR interaction, New Vision (02632.HK) has always adhered to the development strategy of "R&D-driven and innovation-led", continuously increased R&D investment, and built a comprehensive, in-depth and globally radiating patent system, laying a solid foundation for the Company to maintain technological leadership and lead industry development for a long time.Upgrading and Expanding Patent Layout, Core Technologies Leading the IndustryIn 2025, New Vision maintained strong innovation vitality, with 151 new patent applications filed throughout the year, achieving remarkable results in the commercialization of innovative achievements. As of December 31, 2025, the Company had obtained 228 valid patents in total. Its patents and pending applications cover key areas of the entire industrial chain such as HUD optical systems, mechanical structures, software interaction, electronic circuits, testing equipment and methods, forming an all-round, multi-level and comprehensive technical protection network and keeping core technologies firmly in its own hands.In terms of patent structure, the Company focuses on breakthroughs in high-end technologies, with a high proportion of invention patents in the industry. It has focused on laying out hardcore technical patents such as underlying optics, algorithms and core devices to build solid core technical barriers. Meanwhile, it has coordinated the layout of utility model and design patents, balancing product structure optimization, practical application and terminal visual experience, realizing the resonance between technological innovation and market demand.In terms of technical layout, the Company has deeply cultivated four core advantageous fields: optical imaging, AR algorithms, eye box adaptation and system reliability. It has targeted long-standing industry pain points such as blurred imaging, limited field of view, poor adaptability and insufficient stability in extreme environments, continuously strengthened differentiated technical barriers, and built an insurmountable innovative advantage for competitors.Meanwhile, New Vision is accelerating the internationalization of patents. Through the PCT international patent application channel, it has launched the construction of an intellectual property protection system, and gradually built a patent network covering major automotive markets such as Asia, Europe and North America. This global patent layout not only further consolidates the Company's international competitive barriers but also provides solid intellectual property protection for overseas market expansion, laying an important foundation for the Company's localized global operations.Precise Positioning of Core Patents, Tackling Frontier Technologies to Break Industry MonopolyDifferent from the general patent layout in the industry, New Vision focuses more on tackling high-value core patents and precisely positions core technologies and next-generation technology trends in the AR-HUD track.The Company's self-developed bifocal plane AR-HUD mass production technology, relying on its complete independent patent system, solves industry pain points of traditional single-focal-plane HUD such as short imaging distance, poor virtual-real integration and insufficient multi-scenario adaptation. It enables layered imaging of far and near scenes, improving the safety and intelligent experience of vehicle interaction. At present, this technology has been mass-produced on a large scale, becoming a benchmark product for domestic high-end AR-HUD.In the global patent layout, the Company has made advance arrangements for AR-HUD-related technologies, providing core technical patent endorsement for product overseas expansion and building core intellectual property barriers for its participation in competition in the global high-end vehicle interaction market.Empowering Development Through Patents, Industrialization Achievements Highlighting Core CompetitivenessThe strategic significance of patent layout has been fully reflected in the development of New Vision, becoming the core driving force for its high-quality development.First, breaking foreign monopoly and realizing independent control of HUD core technologies. In the past, the vehicle HUD market was long monopolized by Japanese and German enterprises, with prominent "bottleneck" problems in core technologies. Through continuous patent layout and technological innovation, New Vision has gradually got rid of its dependence on foreign capital technologies, provided domestic automakers with independently controllable high-end visual interaction products, and promoted the independent development of China's vehicle HUD industry.Second, building a solid technical moat and consolidating industry-leading position. Through an all-round and multi-level patent layout, New Vision can effectively prevent competitors from imitating technologies and continuously maintain industry-leading technological advantages. Relying on the dual advantages of patented technologies and mass production capacity, the Company has so far obtained 106 vehicle models, covering 23 leading mainstream OEMs. Its market share has steadily increased, making it a benchmark enterprise with excellent technology, scale and reputation in the domestic vehicle AR-HUD field.Third, supporting the implementation of global strategy and accelerating overseas market expansion. Based on PCT international patent layout, the Company has built a patent protection network covering major global markets, escorting product overseas expansion and overseas localized operation. It is reported that New Vision has set up subsidiaries in Germany, Hungary and Japan, initially realizing the transformation of localized global operations. It is continuously expanding its global market territory and enhancing the global influence of China's AR interaction technologies.Efficient Industrialization of Patents, Realizing Commercial Closed-Loop Through Technology Value TransformationDifferent from some pure technology enterprises and pure technology R&D enterprises that emphasize R&D but neglect application, New Vision's core competitiveness lies in the efficient transformation and industrialization of patented technologies. The Company has built a closed-loop transformation system of "patented technologies - mass-produced products - market application", realizing efficient linkage among intellectual property rights, core technologies and commercial value. It has rapidly applied core patented technologies to its two core product matrices, CyberLens and CyberVision. Core products such as bifocal plane AR-HUD and local dimming PGU have achieved large-scale mass production, demonstrating the commercial value of patented technologies.Meanwhile, the application of patented technologies has not only greatly improved core product performance and successfully solved industry pain points such as sunlight backflow, blurred imaging and extreme environment adaptation, but also achieved precise cost control through platform-based design and technical optimization, enhanced product cost performance, helped HUD products quickly penetrate from luxury models to the mass market, and unlocked incremental opportunities in the 100-billion-level vehicle interaction market.In addition, New Vision's core patents also have broad space for external licensing and technical cooperation. Through diversified cooperation modes such as patent licensing, joint technology development and joint R&D, the Company is expected to further explore the derivative value of intellectual property rights, open up new profit spaces, effectively hedge operational risks in a single product market, and further enhance the Company's risk resistance capacity and long-term profitability.From the perspective of industry development, as a leading enterprise in AR interaction, New Vision builds core competitiveness with patents and breaks the industry ceiling with technical reserves. Through precise, three-dimensional and global intellectual property layout, it continuously expands the technical boundary of vehicle AR interaction. The Company has not only broken foreign technological monopoly but also promoted China's AR interaction technology to gradually move onto the global stage. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Sentire(R) Surgical System Receives CE Mark (MDR) and Singapore HSA Dual Certification, Cornerstone Robotics Enters a New Era in its Global Expansion

HONG KONG, May 25, 2026 - (ACN Newswire via SeaPRwire.com) - Cornerstone Robotics (“CSR”), a leading global innovator in surgical robotics based in Hong Kong, China,  is pleased to announce that its Sentire(R) Endoscopic Surgical System (hereinafter “Sentire(R) Surgical System”) has officially received European Union CE mark certification under the Medical Device Regulation (MDR) and simultaneously obtained Singapore Health Sciences Authority (HSA) certification, both covering minimally invasive surgical procedures in General Surgery, Gynecology, Thoracic and Urology. This milestone formally grants the Sentire(R) Surgical System access to both the European and Asia-Pacific markets.Achieving Combined Regulatory Approval and Clinical ValidationThe Sentire(R) Surgical System is a high-end surgical robotic platform that combines clinical workflows with integrated engineering, software, and imaging technologies. Achieving CE certification affirms that its safety, efficacy, and quality management system comply with stringent regulatory standards and is now positioned to serve physicians and patients worldwide.The Company established an early presence in the UK. Since 2025, CSR has partnered with Portsmouth Hospitals University NHS Trust (PHU) to undertake a fully compliant clinical investigation of the Sentire(R) Surgical System, steadily accumulating real-world clinical data to support evidence-based research, training protocol development, and clinical adoption. To date, the Sentire(R) Surgical System has completed numerous complex procedures in the UK, spanning core specialties including urology, gynecology, and upper and lower gastrointestinal surgery.  The investigation achieved the patient outcomes and the clinicians were very satisfied with the system's performance. Concurrently, the Singapore HSA certification, as one of the highly mature and internationally recognised medical device market access systems in the Asia-Pacific, is similarly renowned for its rigorous safety and efficacy evaluations. The Sentire(R) Surgical System's simultaneous achievement of certifications from both the EU and Singapore fully demonstrates Cornerstone Robotics' quality and compliance across different global regulatory frameworks.Deepening Global Presence with Localised ServicesFrom its inception, CSR has embraced a ‘think global, act local’ approach — pursuing a global strategy empowered by local physicians and patients. In Europe, CSR formally established its UK subsidiary in 2025, initiating a one-stop service provision encompassing professional training, clinical technical support, and after-sales service. The Company has already conducted multiple training sessions in the UK, helping clinical teams rapidly build proficiency and confidence in operating the Sentire(R) Surgical System, thereby establishing a solid foundation for scaled commercial rollout.While continuing to deepen its European footprint, Cornerstone Robotics has also been actively expanding its Asia-Pacific collaboration network. Previously, Cornerstone Robotics signed a tripartite Memorandum of Understanding (MOU) with the National Healthcare Group (NHG) and the Lee Kong Chian School of Medicine (LKC Medicine) of Nanyang Technological University, Singapore, to jointly advance the development of Singapore's healthcare innovation ecosystem. In April 2026, Cornerstone Robotics completed the first installation of the Sentire(R) Surgical System in Singapore at Woodlands Hospital under NHG. The system is being made available to surgical teams from multiple local hospitals for system testing, operation training and clinical workflow adaptation assessments. This deployment  leverages the system’s performance in research and training, steadily advancing the adoption of innovative surgical robotic applications in Singapore and the broader Asia-Pacific region.Full-Stack In-House R&D and Vertical Integration: The Foundation for High-Quality Global ExpansionCSR’s full-stack in-house R&D capabilities and vertically integrated model are the foundation of its competitive advantage and global growth strategy.  The Company’s high level of technological integration not only drives strong clinical performance, supply chain resilience, and operational stability, but also enhances agility and supports long-term innovation.Professor Samuel Au, Founder and CEO of Cornerstone Robotics, commented: “Receiving EU CE and Singapore HSA certifications marks a major milestone in Cornerstone Robotics’ evolution from a technology innovator to a global clinical solutions provider. From our first clinical investigation in Portsmouth, UK, to achieving European regulatory approval, each step of the journey reflects our commitment to proprietary innovation, product excellence, and clinical value. Looking ahead, we will continue expanding into key global markets and partnering with leading medical institutions to bring high-quality surgical robotic solutions to more physicians and patients worldwide."The successive approvals of both EU CE and Singapore HSA certifications not only enable market access for the Sentire(R) Surgical System across Europe and Asia-Pacific, but also mark a major milestone in Cornerstone Robotics’ global expansion. In November 2025, the Company successfully completed an oversubscribed financing round of approximately US$200 million, underscoring strong confidence from leading international investors in its long-term growth potential and global commercial capabilities.  Supported by proprietary technological innovation and strong strategic resources, Cornerstone Robotics is well positioned to accelerate the global adoption of high-quality, accessible surgical robotic solutions for physicians and patients worldwide.About Cornerstone Robotics (CSR)Cornerstone Robotics (CSR) is an innovative surgical robotics unicorn driven by the vision of leading medical innovations for a healthier world. It advances surgical care with cutting-edge robotic systems that make high-quality healthcare more accessible and efficient globally. With three global R&D hubs and six business centers worldwide, the company has established a 30,000-square-meter manufacturing facility in China. Developed entirely in-house, the Sentire(R) Surgical System has completed multi-specialty clinical trials and received market approval across China, the European Union and Singapore, advancing high-quality surgical care worldwide.To find out more information, please visit our website at https://en.csrbtx.com/For media inquiries, please feel free to contact Public Relations and Brand Communication Department of Cornerstone Robotics.Email: branding@csrbtx.com Website: https://www.csrbtx.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Cyannova Capital宣布啟動並於香港成功舉辦閉門招待會

香港, 2026年5月25日 - (亞太商訊 via SeaPRwire.com) - 總部位於紐約的投資公司Cyannova Capital ("青藍資本") 近日在其於香港島香格里拉大酒店舉行的閉門招待會上,正式推出其首支投資基金。該基金定位為「資本」與「資源整合平台」的結合體,旨在捕捉由能源、算力、自動化及太空基礎設施融合所引發的新一輪全球大投資週期浪潮。透過構建橫跨北美、中東及亞洲的全球網絡,青藍資本致力於為企業提供長期支持,重點聚焦高科技和新質生產力領域的機會,包括人工智能、可再生能源、機器人技術以及新興的太空經濟。在本次活動中,青藍資本宣布與不同集團(6090.HK)達成戰略合作框架協議。"青藍資本的核心價值遠不止於資金部署。"不同集團董事会主席汪先生表示:"不同非常榮幸能成為青藍資本的首批戰略合作夥伴之一。他們能够整合全球資源,切實幫助企業實現跨國界的規模化擴展。"本次招待會匯聚了超過200位商業領袖及戰略合作夥伴,青藍資本正式對外闡述了這一遠景。招待會期間舉辦了圍繞「數據中心融資」與「太空數據系統未來發展」的爐邊對話,展現了青藍資本對前沿技術領域的深厚承諾。此外,活動現場還舉行了與兩家重要合作夥伴的簽約儀式,進一步鞏固了公司在國際市場促進實質性跨界合作的戰略佈局。"本次招待會是我們在香港乃至整個亞洲市場建立品牌信譽的重要里程碑。" 青藍資本董事總經理 Alessandro Bianchi 表示:"此次與會的戰略合作夥伴質量之高、締結的合作關係之深,充分印證了市場對一個專注於創新企業的跨界投資平台有著強烈需求。我對我們組建的優秀團隊、選定的投資主題以及聚焦的目標地域充滿信心。我們非常期待於 2026 年下半年的資本部署。 "媒體垂詢,請聯繫:Jaysen Laijaysen@cyannovacapital.cominfo@cyannovacapital.com**本公告不應被視為投資建議或投資邀約。**關於青藍資本:青藍資本是一家總部位於紐約的投資公司,專注於能源、計算基礎設施、機器人技術及太空經濟領域。青蓝资本管理著一支配備跨界投資策略的基金,投資範圍橫跨公開與私募市場。公司致力於與成長期至中後期企業結成戰略夥伴,透過提供資金支持與戰略洞察,協助其對接新市場、戰略合作夥伴及赋能技術,從而持續提升企業的長期投資價值。關於不同集團:不同集團(6090.HK)是一家新興的科技驅動型生活方式企業,致力於為全球消費者設計、研發和製造高端嬰童及家庭生活用品。集團主要以旗下旗艦品牌「BeBeBus」運營,在出行用品、睡眠系統、餵養必需品及兒童護理等核心家庭場景中,提供高性能且具備精緻美學設計的解決方案。憑藉其自主研發的先進材料、內部研發實力以及可持續的智能製造網絡,布同集團將實用型育兒工具轉化為高度一體化的科技體驗,為全球現代精英家庭創造原創價值並提升日常尊貴的生活標準。青藍資本與不同集團(6090.HK)達成戰略合作框架協議。Moon Inc. 首席執行官John Riggins於招待會活動上發表主題演講。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

天辰生物通過聆訊:深耕過敏與自身免疫領域 臨床療效全面領先

香港, 2026年5月22日 - (亞太商訊 via SeaPRwire.com) - 生物製藥的黃金時代已然到來,慢性疾病的治療邊界被不斷刷新。在過敏性疾病與自身免疫性疾病治療需求持續釋放的背景下,專注於該領域的天辰生物醫藥(蘇州)股份有限公司(下稱「天辰生物」或「公司」)于5月21日通过港交所聆讯,擬在主板掛牌上市,國金證券(香港)擔任獨家保薦人。作為一家成立於2020年的創新藥企,天辰生物憑藉其自主研發的兩大技術平台,構建起差異化明顯的產品管線,尤其在抗IgE抗體與補體雙功能抗體領域展現出全球競爭力,核心產品臨床進展迅速,市場潛力可期。雙產品齊頭並進,臨床療效顯著天辰生物是一家臨床階段生物製藥公司,專注於過敏性及自身免疫性疾病的生物藥發現與開發。公司已構建針對鼻科、皮膚科、呼吸科、血液科、腎臟科及其他自身免疫性疾病的綜合性生物製劑產品管線,擁有一款核心產品LP-003及一款主要產品LP-005。其中,LP-003是一款具有新型序列設計的抗IgE抗體,主要用於治療季節性過敏性鼻炎(AR)、慢性自發性蕁麻疹(CSU)、過敏性哮喘等。臨床數據顯示,與已上市的同類藥物奧馬珠單抗相比,LP-003在治療CSU方面展現出顯著療效,具有起效迅速、療效良好、作用持久且劑量更低的特点。此外,LP-003與靶點的結合親和力更強,體內作用時間更長,可帶來更佳且更持久的治療效果,從而降低注射頻率,提升患者用藥便利性。目前,LP-003針對季節性AR的III期臨床試驗已完成患者入組,公司預計於2026年第三季度或之前提交生物製品許可申請(BLA),有望成為國內首個獲批用於該適應症的抗IgE抗體藥物。此外,LP-003在CSU、過敏性哮喘、慢性鼻竇炎伴鼻息肉(CRSwNP)及食物過敏等多個適應症上的臨床試驗也在同步推進中。LP-005是一款靶向C5和C3b補體的雙功能抗體融合蛋白,用於治療陣發性睡眠性血紅蛋白尿症(PNH)、補體介導腎臟疾病及全身型重症肌無力(gMG)等。與大多數針對單一靶點的補體抑制劑藥物不同,LP-005可同時作用於補體系統的兩個靶點(C5和C3b),展現出更高且更全面的活性。II期臨床數據顯示,LP-005能有效改善PNH患者的血紅蛋白水平和乳酸脫氫酶水平,安全性良好,且在接受依庫珠單抗治療控制不佳的患者中仍觀察到持續臨床獲益,展現出解決難治性PNH患者治療需求的潛力。目前,LP-005正在中國開展多項II期臨床試驗,評估其治療PNH及補體介導腎臟疾病的療效。未來,公司還將繼續拓展其應用邊界,探索gMG、MAG-PN、ALS等更多補體相關疾病中的應用潛力。兩大技術平台築基 打造差異化創新管線天辰生物的研發能力植根於兩大自有技術平台:高親和力抗體發現平台與雙功能抗體開發平台。這些平台涵蓋生物製劑開發的所有關鍵功能,使公司能夠在早期階段識別並解決潛在的臨床及製造問題,進而聚焦於最具臨床價值、成本優勢與商業潛力的候選藥物。高親和力抗體發現平台涵蓋抗原篩選與製備、動物選擇、抗體篩選方法與策略,以及抗體表徵與評估等環節,有助於生成皮摩爾級親和力及高度可成藥的抗體。經過該平台優化後,核心產品LP-003對IgE的親和力較競品奧馬珠單抗高出860倍。雙功能抗體開發平台突破了傳統抗體構型,具備結構靈活、適用性廣、成藥性高的特點。基於該平台,公司已成功開發出主要產品LP-005,以及多款在研产品,包括針對過敏性疾病的雙功能抗體 LP-00A,針對B細胞介導自身免疫性疾病的雙功能抗體或融合蛋白LP-00C,及針對特 定組織╱器官及適應症優化的雙功能抗體或融合蛋白補體抑制劑LP-00D。在這兩大平台的協同驅動下,天辰生物正持續豐富其在過敏與自身免疫疾病領域的創新產品管線,展現出持續的研發動能與豐厚的產品儲備。市場需求旺盛,藍海空間廣闊從行業前景來看,根據弗若斯特沙利文的報告,中國過敏性疾病藥物市場規模已從2018年的38億美元增長至2024年的81億美元,預計到2030年將達229億美元,該期間複合年增長率達20.1%。其中,生物製劑的市場份額預計將從2024年的19.8%提升至2030年的54.1%。在中國,季節性AR患者群體龐大,但現有治療手段存在明顯侷限。根據弗若斯特沙利文的資料,約60%的季節性AR患者在接受第二代鼻用或口服抗組胺藥及鼻用糖皮質激素治療後,療效仍然不佳。此外,針對中重度AR患者的獲批治療方案和現有藥物的療效均較為有限,且截至2024年底,中國尚無獲批用於AR的生物製劑療法藥物。這一巨大未被滿足的臨床需求,為LP-003提供了難得的市場機遇。作為一款新型抗IgE抗體,LP-003在II期臨床試驗中已展現出優於現有標準治療的潛力,並有望成為中國首個獲批用於季節性AR的生物製劑。與此同時,中國自身免疫性疾病藥物市場也處於快速增長期,預計到2030年將達190億美元。補體抑制劑正從罕見病向常見病領域加速滲透,市場潛力巨大。隨著適應症版圖持續擴張,潛在患者群體不斷壯大,推動補體藥物市場規模穩步攀升,釋放出更廣泛的疾病覆蓋能力與可觀的商業化前景。LP-005凭借在多個補體相關適應症上具備差異化競爭優勢,有望在這片廣闊市場中佔據一席之地。結語天辰生物正處於從臨床階段向商業化邁進的關鍵時期。憑藉差異化的產品管線、領先的臨床進度以及自主研發的技術平台,公司在過敏與自身免疫性疾病領域具備明確的成長路徑與市場機遇。隨著核心產品臨床試驗的穩步推進,天辰生物有望在中國創新藥浪潮中脫穎而出,成為過敏與自免領域的重要力量,為患者帶來更多創新治療選擇。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Six Factors to Consider When Opting for a Credit Line in Singapore

SINGAPORE, May 22, 2026 - (ACN Newswire via SeaPRwire.com) - In Singapore's fast-paced economy, managing cash flow effectively is key to maintaining sound financial health. Whether you face an unexpected bill or plan a large purchase, choosing an optimal credit line may provide the flexible funding you need.Unlike a fixed loan, a credit line allows you to withdraw funds only when necessary and pay interest only on the amount you actually use. Before you apply, consider these essential factors to ensure you use this financial tool responsibly.Evaluate the interest rate and total costThe most critical factor for any credit line is the interest rate, as it determines the total repayment amount. Credit Cards in Singapore typically charge interest rates in the range of 25-28% per annum, making them less suitable for long-term use.In contrast, a dedicated credit line often provides more competitive rates for short-term borrowing. Always ensure to check the Effective Interest Rate (EIR), which reflects the overall cost of borrowing, including interest and applicable fees, and gives you a clearer picture of the actual liable cost.Understand your repayment capacityBefore using your credit line, you must have a clear understanding of your current financial standing. This requires reviewing your bank balance, existing debt, and monthly income to see how much you can comfortably repay.A common mistake is treating a credit line as open-ended debt. Instead, you should create a structured repayment plan that fits your actual take-home pay. Matching your payments to your income helps prevent interest from compounding and keep your finances balanced.Check for flexibility and speedOne of the main reasons to opt for a credit line is the access to funds during unforeseen circumstances. Many banks in Singapore may offer fast approval and digital fund transfers, allowing customers to respond to urgent needs in a timely manner, subject to the bank's credit assessment and eligibility criteria.You may also wish to look for a credit line that offers flexible withdrawal options, such as via an ATM card or internet banking. This can support access to funds for unexpected or essential expenses when required. Having this access may help reduce delays associated with the long application process when access to funds are needed.Calculate the total cost of borrowingBeyond the interest rate, you should look at the extra fees that come with a credit line. Some accounts charge an annual fee or a processing fee when you first open the account. These small costs can add up and increase the total amount you owe the bank.A smart way to save money is to find a credit line that offers a fee waiver for the first year or offers promotional interest rates. You should also check if there are any charges for late payments or exceeding your credit limit. Knowing these numbers early helps you avoid surprises and keeps your borrowing costs as low as possible.Consider promotional periods and balance transfersMany lenders offer promotional interest rates to new customers for a fixed period. If you already carry high-interest debt, you can use a credit line or Balance Transfer to consolidate those costs.This strategy may help you control your interest outflow while you focus on clearing the principal balance. However, you must ensure you can repay the full amount before the promotional period ends to avoid higher standard rates.Review your long-term financial goalsWhile a credit line offers a short-term solution, it should not derail your long-term savings goals. Once you settle your immediate financial needs, you should focus on rebuilding your emergency reserves.Allocating a small percentage of your income to a reserve fund reduces your potential reliance on credit. A resilient financial structure allows you to navigate future expenses more effectively and support financial planning over the long run.Final thoughtsChoosing the right credit line is a major step in taking control of your financial journey. By comparing interest rates, checking for fees, and planning your repayments, you can use credit as a helpful tool rather than a burden, when manage appropriately. A well-managed credit line may help to support cash flow management for anticipated or unplanned expenses.Disclaimer: This content is published by iQuanti Singapore Pte Ltd, an external marketer engaged and compensated by UOB Ltd.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

雲頂新耀獲主要股東康橋資本增持 全球化佈局有望持續受益

香港, 2026年5月22日 - (亞太商訊 via SeaPRwire.com) - 雲頂新耀發佈公告稱,公司主要股東康橋資本於2026年5月20日至21日期間,通過公開市場購入公司普通股60.05萬股,交易總金額約1920萬港元,平均價格約為每股31.91港元。據悉,此次購入為康橋資本對雲頂新耀股份的再度增持。自2025年12月以來,康橋資本及公司董事已連續在公開市場累計購入超過306.2萬股公司股份,累計交易總金額超過1.138億港元。另外,公司非執行董事、董事會榮譽主席兼主要股東傅唯先生於2026年3月27日及5月14日兩次增持公司股份,分別購入86萬股和66萬股,總金額約3270萬港元及2070萬港元。康橋資本及公司董事表示,基於對公司未來前景與長期發展的堅定信心,在遵守相關法律法規的前提下,不排除未來在適當時候進一步增持公司股份的可能性。此次增持正值康橋資本宣佈與歐洲領先的醫療健康專業投資機構GHO Capital達成合併協議之際。雙方採用50:50平等合併模式,預計於2027年初完成。合併後平台資產管理規模將超過210億美元,有望成為全球規模最大的醫療健康投資資產管理平台,覆蓋北美、歐洲及亞太地區,三大區域合計佔全球醫療健康研發投入約90%。分析人士認為,康橋資本與GHO Capital的合併,將進一步增強雲頂新耀國際化發展的資源協同與全球佈局能力。雲頂新耀2025年營收同比增長142%,核心產品耐賦康(R)銷售收入達14.43億元,同比增長超300%。根據公司此前發佈的2030戰略,雲頂新耀目標到2030年實現營收突破150億元、商業化產品超20款,加速向全球化綜合性生物製藥公司邁進。隨著全球資源網絡進一步整合,公司有望加快創新產品國際化及全球商業佈局。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GTJAI Won Two Awards at HR Asia 2026

HONG KONG, May 22, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, HR Asia, a leading authority in human resources media in Asia, officially announced its award results in 2026. Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, has won two prestigious awards — “Best Companies to Work for in Asia” and “Tech Empowerment Award” — in recognition of its outstanding practices in workplace development, employee care, and digital enablement.HR Asia is a widely influential HR media brand in Asia. Through independent employee surveys and expert judging, it recognizes companies that demonstrate outstanding performance in employer branding, talent development, workplace culture, and technological innovation. The “Best Companies to Work for in Asia” award aims to honor companies that adhere to a people-oriented approach, build a high-quality workplace ecosystem, and foster the shared growth of employees and the organization. The “Tech Empowerment Award” recognizes companies that leverage innovative technologies to enhance employee productivity, engagement, and overall work efficiency, setting industry benchmarks in digital transformation and workplace empowerment. (The Human Resources team of GTJAI Accepted the Awards)GTJAI has always regarded talent as its core driving force. It continuously improves its systems for talent acquisition, development, incentives, and career progression, while building diversified career pathways and providing growth support that covers professional capabilities, management competencies, and an international perspective. At the same time, GTJAI places great emphasis on fostering an inclusive, equitable, and healthy workplace atmosphere, with a focus on employee experience and work-life balance, creating an open, collaborative, and positive team environment. In terms of technology empowerment, GTJAI drives the deep integration of financial technology with internal management, office collaboration, and business operations. By leveraging innovative technology solutions, it optimizes management processes, enhances collaboration efficiency, and improves employee work experience. Through digital tools, it boosts organizational efficiency and employee satisfaction, providing strong support for steady business development and global expansion.As a key international business platform under Guotai Haitong Group, GTJAI is headquartered in Hong Kong and serves global markets. It adheres to a compliant and prudent management philosophy, continuously building a competitive employer brand amid its business development while attracting and nurturing outstanding financial talent. The recognition of receiving two prestigious HR Asia 2026 awards affirms GTJAI’s efforts in employer brand building, talent management practices, and technology empowerment achievements, and will further enhance its brand image within Asia’s financial industry and human resources sector. GTJAI will take this award as an opportunity to fulfill corporate responsibilities, promote the shared growth of employees and the Company, enhance professional service capabilities and global market influence, leverage cross-border financial advantages, bring together top-tier talent, create long-term value for clients, provide a broad development platform for employees, and contribute to the development of Hong Kong as an international financial center.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

國泰君安國際斬獲HR Asia 2026年度兩項大獎

香港, 2026年5月22日 - (亞太商訊 via SeaPRwire.com) - 近日,亞洲權威人力資源媒體HR Asia正式公布2026年度獎項評選結果,國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」,股份代號:1788.HK)憑藉在職場建設、員工關懷與數字化賦能等方面的優秀實踐,一舉斬獲「亞洲最佳企業雇主」及「科技賦能獎」兩項重要獎項。HR Asia是亞洲具有廣泛影響力的人力資源專業媒體品牌,通過獨立員工問卷調查與專業評審,評選在雇主品牌建設、人才發展、職場文化及科技創新等方面表現突出的企業。本次「亞洲最佳企業雇主」獎項,旨在表彰堅持以人爲本、構建優質職場生態、推動員工與企業共同成長的優秀企業;「科技賦能獎」用于表彰運用創新技術提升員工生産力、敬業度與整體工作效率,在數字化轉型與職場賦能方面樹立行業標杆的企業。 (國泰君安國際人力資源團隊登臺領獎)國泰君安國際始終視人才爲核心動力,持續完善人才引進、培養、激勵與發展體系,搭建多元化職業發展通道,提供覆蓋專業能力、管理能力與國際化視野的成長支持。同時,公司注重構建包容、平等、健康的職場氛圍,關注員工體驗與工作生活平衡,營造開放協作、積極向上的團隊環境。在科技賦能方面,國泰君安國際推動金融科技與內部管理、辦公協同、業務運營深度融合,通過創新技術解决方案優化管理流程、提升協作效率、改善員工工作體驗,以數字化工具提升組織運行效率與員工滿意度,爲業務穩健發展與全球化布局提供有力支撑。作爲國泰海通集團旗下重要的國際化業務平台,國泰君安國際立足香港、服務全球市場,堅守合規穩健經營理念,在業務發展中持續打造具有競爭力的雇主品牌,吸引幷培養優秀金融人才。此次榮獲HR Asia 2026兩項權威獎項,是對國泰君安國際雇主品牌建設、人才管理實踐與科技賦能成果的認可,也將進一步提升其在亞洲金融行業及人力資源領域的品牌形象。國泰君安國際將以此次獲獎爲契機,踐行企業責任,推動員工與企業共同成長,提升專業服務能力與全球市場影響力,發揮跨境金融優勢,彙聚優秀人才,爲客戶創造長期價值,爲員工提供廣闊發展平臺,爲香港國際金融中心建設貢獻力量。關於國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高質量、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的信息請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit

HONG KONG, May 22, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines announced that its substantial shareholder, CBC Group, purchased 600,500 ordinary shares of the Company on the market from 20 May 2026 to 21 May 2026. The total consideration for the transaction was approximately HK$19.2 million, representing an average purchase price of approximately HK$31.91 per share.The purchase represents a further increase in CBC Group’s shareholding in the Company. Since December 2025, CBC Group and the Directors have cumulatively purchased more than 3.062 million shares of the Company on the market for a total consideration of more than HK$113.8 million in aggregate. Additionally, Mr. Wei Fu, a non-executive Director, the honorary chairman of the Board and a substantial shareholder of the company, increased his holdings of the Company's shares twice on 27 March and 14 May 2026. He purchased 860,000 shares and 660,000 shares respectively, with corresponding transaction amounts of approximately HK$32.7 million and HK$20.7 million. CBC Group and the Directors stated that, based on their firm confidence in the Company’s future prospects and long-term development, and subject to compliance with the applicable laws and regulations, they do not rule out the possibility of further increasing their shareholdings in the Company when appropriate.The increased shareholding comes as CBC Group recently announced a merger agreement with GHO Capital, a leading European healthcare-specialist investment firm. The transaction will be structured as a 50:50 merger of equals and is expected to close in early 2027. Following completion, the combined platform is expected to manage more than US$21 billion in assets, potentially becoming the world’s largest healthcare-focused investment management platform. The combined entity will span North America, Europe, and Asia-Pacific — regions that together account for approximately 90% of global healthcare R&D investment.According to analysts, the merger between CBC Group and GHO Capital is expected to further enhance resource synergy and global expansion capabilities for Everest Medicines. Everest Medicines achieved 142% year-over-year revenue growth in 2025, with core product NEFECON® generating RMB 1.443 billion in sales, representing over 300% year-over-year growth. Under the Company's previously announced 2030 Strategy, Everest Medicines aims to achieve revenue exceeding RMB 15 billion and expand its commercialized product portfolio to more than 20 products by 2030, accelerating its transformation into a global integrated biopharmaceutical company. With the further integration of global resource networks, the Company is expected to accelerate the internationalization of its innovative products and its global commercial footprint. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

東森集團全面擁抱AI 東森自然美與百度啟動戰略合作

香港, 2026年5月21日 - (亞太商訊 via SeaPRwire.com) - 亞洲知名美容護膚集團自然美生物科技有限公司(「自然美」)及其附屬公司(以下簡稱「集團」;香港上市股份代號:00157)欣然宣佈,東森集團AI戰略佈局再下一城。集團於5月19日在北京正式與百度簽署戰略合作協議,雙方將聚焦AI科美、大健康、智慧營銷、AI肌膚檢測、數字化門店與智能服務等核心應用,全面推進人工智慧於美業與消費產業鏈的深度落地。簽約儀式於百度北京總部舉行,由集團行政總裁鄭吉崇與百度智慧雲智慧工業總經理李超代表雙方完成簽署,東森集團總裁王令麟及百度集團副總裁袁佛玉雙雙出席見證。 第一排左1東森自然美集團行政總裁鄭吉崇、第一排左2百度智慧雲智慧工業總經理李超、第二排左1東森集團總裁王令麟、第二排左2百度集團副總裁袁佛玉此次合作不僅是AI技術合作,更被視為東森集團深化AI轉型的重要里程碑。近年來,東森持續推動AI升級,繼與AWS、微軟等國際科技平台合作後,此次再攜手百度,進一步擴大集團於AI、大數據與智慧服務領域的整體布局。集團表示,AI已從技術工具,逐步成為企業升級與產業重構的重要引擎。尤其美業正快速從傳統產品導向,轉向數據驅動與智慧服務導向,AI將成為下一階段產業競爭的重要關鍵。 東森集團總裁王令麟此次百度選擇與集團展開長期深度合作,並非單純技術輸出,而是基於東森集團完整產業生態的戰略布局。東森集團橫跨媒體、電商、零售、生技製造等多元產業,擁有龐大的會員基礎、內容體系與消費場景;而深耕亞洲美業55年的東森自然美,則具備完整研發、生產、渠道與門店體系。相較於單一美容品牌,東森擁有更完整的數據場景與產業轉化能力,使AI不僅能應用於消費端,更可深入媒體、零售、製造與供應鏈體系,實現真正的產業級落地。業界權威解讀,此次合作代表百度正加速AI技術於傳統消費產業中的規模化應用。根據雙方簽署的合作協議,集團與百度生態系公司將建立長期且深度的合作架構,並將共同推進AI創新中心的建立,以及未來相關AI技術應用向更多產業業態延伸。集團近年來持續推動「AI科美、大健康」核心戰略,並積極將AI大模型與數據分析技術導入企業經營全鏈路,包括消費者需求洞察、產品研發、會員經營、門店管理、智慧營銷與售後服務等環節,逐步建立以數據驅動決策的營運體系。東森自然美集團行政總裁鄭吉崇表示,AI的價值不只是提升效率,更重要的是重新定義企業與消費者的互動方式。東森自然美正從傳統美業品牌,逐步升級為具備AI資料能力、智慧服務能力與全球化營運能力的新世代產業平臺。藉百度技術的加持,集團將會躍升為AI資料+服務的公司。百度集團副總裁袁佛玉則表示,百度將持續通過AI大模型、智能雲與數據技術等能力,與東森集團攜手推動智慧營銷、智能服務與數據平台建設,加速AI在東森集團實際產業場景中落地。 百度集團副總裁袁佛玉未來,雙方將重點推動AI智慧肌膚檢測、個人化護理方案生成、AR虛擬試妝、AI智慧客服、數位人直播、智慧門店、智慧製造與供應鏈追溯等多項應用,並共同建構亞洲最權威的肌膚健康大資料庫,進一步提升產品研發、精准行銷與智慧服務能力。東森集團總裁王令麟也期許,未來將持續深化智慧科技佈局,透過與全球頂級AI企業合作,加速推動媒體、零售、美業與大健康等多元產業的數位轉型,打造具備AI資料能力、智慧服務能力與產業整合能力的新世代產業平台。關於自然美生物科技有限公司(香港上市股份代號:00157)東森自然美作為中國領先的上市美容護膚品牌,自 1972 年創立以來,始終以「自然就是美」為核心理念,深耕行業 55 年。依托「AI科美、大健康」戰略驅動,品牌在全球佈局2,093 家門店,成為國人自主創立的跨國生物科技標桿,持續引領美妝護膚行業革新。傳媒聯絡方法:縱橫財經公關顧問有限公司吳燕霞電話:2864 4812電郵:mandy.go@sprg.com.hk張銘伊電話 : 2114 4903電郵 : maggie.zhang@sprg.com.hk 網站: http://www.sprg.com.hk  Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Eastern Media Group Fully Embraces AI Natural Beauty Launches Strategic Partnership with Baidu

HONG KONG, May 21, 2026 - (ACN Newswire via SeaPRwire.com) - Natural Beauty Bio-Technology Limited ("Natural Beauty"), a renowned dual-listed beauty and skincare group in Asia, together with its subsidiaries (the "Group"; Hong Kong stock code: 00157), is pleased to announce a major milestone in Eastern Media Group’s AI strategy. The Group officially signed a strategic cooperation agreement with Baidu in Beijing on May 19. The two parties will focus on core applications such as AI beauty technology, holistic health, smart marketing, AI skin analysis, digital retail stores, and intelligent services to comprehensively advance the integration of AI across the beauty and broader consumer industry value chain. The signing ceremony was held at Baidu’s Beijing headquarters. where the agreement was signed by Mr. Cheng Chi-chung, Chief Executive Officer of the Group, General Manager of Smart Industry at Baidu Intelligent Cloud, signed the agreement on behalf of each party. Gary Wang, President of Eastern Media Group, and Yuan Foyu, Vice President of Baidu Group, attended and witnessed the event. From left, front row: Cheng Chi-chung, CEO of Natural Beauty; Li Chao, General Manager of Smart Industry at Baidu Intelligent Cloud; Back row: Gary Wang, President of Eastern Media Group; Yuan Foyu, Vice President of Baidu GroupThis collaboration is not only a partnership in AI technology but also represents an important milestone in Eastern Media Group’s ongoing AI transformation. In recent years, Eastern Media Group has continued to drive AI upgrades. Following collaborations with international technology platforms such as AWS and Microsoft, this new partnership with Baidu is set to further expand the Group’s overall presence in the fields of AI, big data, and intelligent services.The Group stated that AI has gradually evolved from a technological tool into a critical engine for corporate upgrading and industrial restructuring. In particular, the beauty industry is rapidly shifting from a traditional product-oriented model to one driven by data and intelligent services, with AI set to become a core competitive advantage in the next phase of industry development. Gary Wang, President of Eastern Media GroupBaidu’s decision to enter into a long-term, in-depth partnership with the Group goes beyond mere technology licensing; it is a strategic move built on Eastern Media Group’s comprehensive industrial ecosystem. Eastern Media Group’s businesses span media, e-commerce, retail, biotech manufacturing, and other diverse sectors, boasting a large member base, a content ecosystem, and a range of consumption scenarios. Meanwhile, Natural Beauty, with 55 years of experience in the Asian beauty industry, operates a fully integrated system covering R&D, production, distribution channels and physical stores.Compared with individual beauty brands, Eastern Media Group possesses more comprehensive data scenarios and stronger industrial transformation capabilities, enabling AI to be applied not only on the consumer side but also across media, retail, manufacturing, and supply chain systems, thereby achieving true industry-wide implementation. The market also views this collaboration as a sign that Baidu is accelerating the large-scale deployment of AI technologies in traditional consumer industries.Under the cooperation agreement, the Group and companies within the Baidu ecosystem will establish a long-term, deeply integrated cooperation framework. The parties will also jointly build an AI Innovation Center and extend AI applications to more industrial sectors in the future.In recent years, the Group has continued to advance its core strategy of “AI Beauty Technology, Holistic Health,” proactively integrating large AI models and data analytics technologies across its entire business value chain. This spans consumer demand insights, product R&D, membership management, store operations, smart marketing, and after-sales services, thereby gradually establishing a data-driven decision-making operating system.Cheng Chi-Chung, Chief Executive Officer of the Group, stated: “The value of AI extends far beyond efficiency gains - it fundamentally redefines how businesses interact with consumers. Natural Beauty is evolving from a traditional beauty brand into a next-generation industrial platform with AI data capabilities, intelligent service capabilities and global operational capacity. With Baidu’s technological support, the Group will transform into an ‘AI data + service’ enterprise.”Yuan Foyu, Vice President of Baidu, commented that stated that Baidu will continue to leverage its capabilities in large AI models, intelligent cloud and data technologies, and work hand in hand with Eastern Media Group to drive the development of smart marketing, intelligent services and data platforms, accelerating the implementation of AI in Eastern Media Group’s real-world industrial scenarios. Yuan Foyu, Vice President of Baidu GroupMoving forward, the two parties will prioritize the development of multiple applications, including AI-powered smart skin analysis, personalized skincare solution generation, AR virtual try-on, AI smart customer service, digital human live streaming, smart stores, intelligent manufacturing and supply chain traceability. They will also jointly build Asia’s most authoritative skin health big database, further enhancing capabilities in product R&D, precision marketing and intelligent services.Gary Wang, President of the Eastern Media Group, expressed his vision: “Looking ahead, we will continue to deepen our smart technology deployment. By collaborating with world-leading AI enterprises, we will accelerate the digital transformation of our media, retail, beauty and holistic health businesses, building a next-generation industrial platform with AI data capabilities, intelligent service expertise and industrial integration capabilities.”About Natural Beauty Bio-Technology Limited (Hong Kong stock code:00157)A China’s leading listed beauty and skincare brand established in 1972, has championed its core philosophy of "Natural Beauty Is True Beauty" for 55 years. Driven by its "AI Technology, Beauty Industry, Holistic Health" integrated strategy, the brand operates a global network of over 2,093 outlets. As a Chinese-origin transnational biotech pioneer, Natural Beauty continues to propel innovation in the cosmetics and skincare sector.Media enquiriesStrategic Financial Relations LimitedMandy GoTel: +852 2864 4812Email: mandy.go@sprg.com.hk Maggie ZhangTel: +852 2114 4903Email: maggie.zhang@sprg.com.hk Website:http://www.sprg.com.hk   Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GA-ASI Completes First Flight of MQ-9B With AEW Pods

SAN DIEGO, May 21, 2026 - (ACN Newswire via SeaPRwire.com) - General Atomics Aeronautical Systems, Inc. (GA-ASI) flew its MQ-9B Remotely Piloted Aircraft for the first time with Airborne Early Warning (AEW) pods. The much-anticipated AEW capability is being provided through a partnership with Saab. Once the AEW sensor, named LoyalEye, is made available to MQ-9B operators and new customers, it will deliver persistent and cost-effective air surveillance capabilities in regions where it is currently unavailable.GA-ASI conducted a validation flight of MQ-9B using AEW radar pods on May 19 from GA-ASI's Desert Horizon flight operations facility in Southern California using a company-owned aircraft. The flight signaled the first step in a development process that is expected to take several months and culminate with a full-capability demonstration later this year.GA-ASI and Saab announced their partnership last year with the intention of bringing AEW capability to the MQ-9B platform.MQ-9B models include the SkyGuardian® and SeaGuardian®, the United Kingdom's MQ-9B variant known as Protector, and the new MQ-9B STOL (Short Takeoff and Landing) configuration currently in development for naval aircraft carriers."AEW for MQ-9B will offer critical aloft sensing to defend against tactical air munitions, guided missiles, drones, fighter and bomber aircraft, and other threats. Operational availability for a medium-altitude, long-endurance UAS is the highest of any military aircraft, and as an unmanned platform, its aircrews are not put into harm's way," said GA-ASI President David R. Alexander."This partnership integrates MQ-9B with LoyalEye, equipping operators with vital information for critical decision-making. LoyalEye extends the capabilities of manned systems, and it offers persistent surveillance and greater operational flexibility. This enhances situational awareness and boosts mission success," said Carl-Johan Bergholm, Senior Vice President and Head of Business Area Surveillance at Saab.GA-ASI and Saab's AEW offering will span a wide range of applications, including early detection and warning, long-range detection and tracking, and simultaneous target tracking and flexible system integration - all over line-of-sight and SATCOM connectivity.About GA-ASIGeneral Atomics Aeronautical Systems, Inc., is the world's foremost builder of Unmanned Aircraft Systems (UAS). Logging more than 9 million flight hours, the Predator® line of UAS has flown for over 30 years and includes MQ-9A Reaper®, MQ-1C Gray Eagle®, MQ-20 Avenger®, and MQ-9B SkyGuardian®/SeaGuardian®. The company is dedicated to providing long-endurance, multi-mission solutions that deliver persistent situational awareness and rapid strike.For more information, visit www.ga-asi.com.Avenger, EagleEye, Gray Eagle, Lynx, Predator, Reaper, SeaGuardian, and SkyGuardian are trademarks of General Atomics Aeronautical Systems, Inc., registered in the United States and/or other countries.GA-ASI Media RelationsGeneral Atomics Aeronautical Systems, Inc.ASI-MediaRelations@ga-asi.com(858) 524-8101SOURCE: General Atomics Aeronautical Systems, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GA-ASI 完成搭載空中預警吊艙的 MQ-9B 首飛

加州聖地牙哥, 2026年5月21日 - (亞太商訊 via SeaPRwire.com) - 通用原子航空系統公司(GA-ASI)首次成功試飛搭載空中預警(AEW)吊艙的 MQ-9B 遙控無人機。這項備受期待的空中預警能力,是透過與薩博(Saab)的合作夥伴關係所實現。一旦名為「LoyalEye」的空中預警感測器能提供給 MQ-9B 操作單位及新客戶,它將在目前尚無此類能力的地區,提供持續且具成本效益的空中監控能力。GA-ASI於5月19日從其位於南加州的「沙漠地平線」(Desert Horizon)飛行作業基地,使用公司自有飛機,對搭載AEW雷達吊艙的MQ-9B進行了驗證飛行。此次飛行標誌著開發進程的第一步,預計將耗時數月,並於今年稍晚進行全功能演示。GA-ASI 與薩博(Saab)去年宣布合作,旨在為 MQ-9B 平台整合空中預警能力。MQ-9B 系列機型包含「天衛者」(SkyGuardian®)與「海衛者」(SeaGuardian®)、英國的 MQ-9B 衍生型「守護者」(Protector),以及目前正為海軍航空母艦開發中的新型 MQ-9B 短距起降(STOL)配置。「MQ-9B的空中早警系統將提供關鍵的高空偵測能力,用以防禦戰術航空彈藥、導引飛彈、無人機、戰鬥機與轟炸機,以及其他威脅。中空長航時無人機系統的作戰可用性高於任何軍用飛機,且作為無人平台,其機組人員不會身處險境,」GA-ASI總裁大衛·R·亞歷山大表示。「此合作將 MQ-9B 與 LoyalEye 系統整合,為操作人員提供關鍵決策所需的重要資訊。LoyalEye 擴展了有人駕駛系統的能力,並提供持續監控與更大的作戰靈活性。這將提升戰場態勢感知能力,並提高任務成功率,」薩博公司資深副總裁兼監控業務部門負責人卡爾-約翰·伯格霍姆(Carl-Johan Bergholm)表示。GA-ASI 與薩博的空中預警(AEW)解決方案將涵蓋廣泛的應用領域,包括早期偵測與預警、長程偵測與追蹤,以及同步目標追蹤與靈活的系統整合——所有功能皆透過視距內通訊及衛星通訊(SATCOM)連接實現。關於 GA-ASI通用原子航空系統公司(General Atomics Aeronautical Systems, Inc.)是全球首屈一指的無人機系統(UAS)製造商。「捕食者®」(Predator®)系列無人機系統累積飛行時數已超過 900 萬小時,服役逾 30 年,包含 MQ-9A「死神®」(Reaper®)、MQ-1C「灰鷹®」(Gray Eagle®)、MQ-20「復仇者®」(Avenger®)以及 MQ-9B「天衛®」(SkyGuardian®)/「海衛®」(SeaGuardian®)。該公司致力於提供長航時、多任務解決方案,以實現持續的戰場態勢感知與快速打擊能力。欲了解更多資訊,請造訪 www.ga-asi.com 。Avenger、EagleEye、Gray Eagle、Lynx、Predator、Reaper、SeaGuardian 及 SkyGuardian 均為通用原子航空系統公司(General Atomics Aeronautical Systems, Inc.)於美國及/或其他國家註冊的商標。GA-ASI 媒體關係通用原子航空系統公司ASI-MediaRelations@ga-asi.com (858) 524-8101消息來源:通用原子航空系統公司 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

The World’s First Global Energy Drink Ranking Accidentally Revealed Something Much Bigger

MONTREAL, QUEBEC, May 21, 2026 - (ACN Newswire via SeaPRwire.com) - A beverage expert spent six months collecting and assessing energy drinks from all six continents to create the world's first objective global ranking of the category. But during the process, an unexpected discovery emerged: depending on the continent, energy drinks are fundamentally different products.WORLDWIDE COLLECTION & ASSESSMENTPat Eckert, an internationally recognised German beverage professional and certified water sommelier, realised that nobody had ever created an objective global ranking of energy drinks. This was despite energy drinks being one of the world's largest and most discussed beverage categories, while cars, phones, wines, films, and many other consumer sectors already have serious worldwide rankings.So over roughly half a year, he and his team collected energy drinks from all six inhabited continents and assessed each one using the same professional 36-criteria framework, focused on measurable product quality, ingredients, transparency, and formulation standards. Top-performing products were submitted for laboratory testing and analytical verification. This became the Six Continents Index - built to be professional, rigorous, and objective.The original goal was simple: to identify which brands objectively perform best worldwide.However, during the assessment, another finding emerged almost accidentally: energy drinks are not really the same category across continents. Different regions follow very different product philosophies - from Europe's strong focus on pasteurisation, to Asia's preference for real sugar, to North America's heavy reliance on artificial formulations, sweeteners and preservatives.So the project ultimately became both the world's first objective global energy drink ranking and a snapshot of how differently the category is formulated around the world.THE SHOCK FINDINGS· Europe goes natural. South America goes artificial. 85.7% of European energy drinks were pasteurised, compared with 12% in North America and under 1% in South America.· Asia still uses real sugar. North America barely does. In Asia, 78.9% of energy drinks used real sugar. In North America: just 8%. They are effectively drinking a different product.· North America runs on sweeteners. The rest of the world mostly does not. 84% of North American energy drinks relied entirely on artificial sweeteners. In Europe: just 4.2%. In Asia, Australia, South America, and Africa: almost none.· Australia vitaminizes. North America simplifies. Australian drinks averaged 4.2 vitamins per product, compared with just 2.9 in North America.· Aspartame is still used worldwide, especially in Africa Aspartame (classified by WHO/IARC as "possibly carcinogenic to humans" (Group 2B)), was used in 10.5% of products worldwide, with 43% of those aspartame-containing products found in Africa.· BPA-free labelling was almost invisible worldwide. Only 1.4% of the global sample clearly carried BPA-free labelling.· North America - the world's largest energy drink market by revenue - ranked last overall among the six continents.Europe pasteurises. North America sweetens artificially. Asia uses real sugar. Australia vitaminizes. Same category, completely different product philosophies.GLOBAL BRAND NOTESAmong the many brands assessed across six continents, two stood out for reasons beyond the ranking. Red Bull was the only energy drink brand found in virtually every market assessed worldwide, while Japan's Lipovitan-D was the oldest brand in the study, having been on the market since 1962.HIGHEST-SCORING PRODUCTSAt the continental level, Europe achieved the highest overall score in the index. Australia & Oceania ranked second, followed by Asia in third place.At brand level, HELL Energy from Hungary achieved the highest overall score for objective product quality in the index. Second place went to 28 BLACK from Germany, followed by TAKE OFF, also from Germany.FULL FINDINGSFurther findings, methodology, and background information are available on request at www.sixcontinentsindex.comABOUT THE PROJECTThe Six Continents Index was led by Pat Eckert and his team. Eckert is a German certified water sommelier and independent beverage expert whose previous work has been featured by The Guardian, ABC News, The Telegraph, L'Express, Der Spiegel, and the BBC.Assessed brands were not notified in advance, did not apply, and had no involvement in the evaluation. No paid participation, sponsorship, or commercial influence played any role.MEDIA CONTACTBrand: Fine LiquidsContact: Pat EckertWebsite: https://sixcontinentsindex.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

OneRobotics Launches World Action Model OneModel 1.7, Achieving 99% Success in Real-Robot Tests

SHENZHEN, May 21, 2026 - (ACN Newswire via SeaPRwire.com) - May 20, 2026, OneRobotics (6600.HK), a leading embodied AI robotics company listed on the Hong Kong Stock Exchange, announced the launch of its proprietary World Action Model, OneModel 1.7 FrontoStria-RL. The model is designed for real-world deployment in home and service robots, serving as OneRobotics’ core model foundation for advancing the large-scale implementation of embodied AI.On LIBERO, a standard benchmark for embodied AI, OneModel 1.7 achieved an average success rate of 99%, outperforming leading open models including π0.5, GR00T-N1.5 and OpenVLA-OFT, according to the company. In real-robot deployment, the model reached a 99% success rate on daily manipulation tasks and a 97% success rate on high-precision tasks, the company said.Built on OneRobotics’ self-developed RL-Latent World Action Model architecture, or RL-LWAM, OneModel 1.7 integrates three core modules: a World Model for generalization across diverse environments, the Understand Expert for task comprehension and skill scheduling, and the Action Expert for precise execution. These modules are implicitly connected through Predictive Policy Latent, an implicit mechanism designed to link high-level world understanding with low-level action policies without relying on explicit intermediate images or coordinate transfers.The model is designed to address key challenges in home robotics, where robots must operate in unstructured environments, handle unfamiliar objects, adapt to changing layouts and lighting conditions, and complete multi-stage physical tasks with precision. In real-world testing, OneModel 1.7 was applied to tasks including laundry handling, clothes folding, dishwasher operation, conveyor-belt picking, test-tube handling, cup stacking and coffee-bean pouring. It was also validated in a human-robot table tennis rally scenario, demonstrating responsiveness in high-dynamic interaction tasks.The launch comes as OneRobotics accelerates the real-world deployment of embodied AI. The company recently secured a RMB45 million municipal contract in Shenzhen to build an embodied AI data infrastructure center, which will support hardware testing, large-scale data collection and model validation in real-world environments. The project is expected to strengthen OneRobotics’ data closed-loop capabilities for embodied AI model training, algorithm validation and application incubation.OneRobotics has also attracted growing international attention. Japan’s public broadcaster NHK recently conducted a feature interview with the company, focusing on its technical roadmap, product capabilities and commercialization progress in embodied home robotics. During the interview, OneRobotics’ onero H1 demonstrated autonomous task execution in a real home environment, showcasing the company’s progress in bringing embodied AI from laboratory research into everyday household applications.OneModel 1.7 is part of OneRobotics’ broader “One Brain, Multiple Embodiments” strategy in which a single AI model architecture is deployed across different robotic form factors, under which the company aims to reuse and continuously improve core AI capabilities across different robotic forms and application scenarios. OneRobotics’ product portfolio spans home services, sports and wellness, and intelligent companionship, with products available in more than 90 countries and regions.OneRobotics said that as embodied AI moves into the real world, progress will depend not only on larger model parameters or isolated demonstrations, but on model systems that can combine generalized understanding, precise execution and continuous evolution. OneModel 1.7 FrontoStria-RL represents a key step in this direction, supporting the company’s continued model iteration across real home and service scenarios and helping robots become more adaptive, evolvable and reliably useful over time.About OneRoboticsOneRobotics (Shenzhen) Co., Ltd. (6600.HK) is a globally leading AI embodied home robotics company, committed to building an embodied intelligence ecosystem for home scenarios, guided by its core technological philosophy of "One Brain, Multiple Embodiments". Centering on its proprietary AI brain "OneModel", the company focuses on embodied AI technologies for home scenarios and develops robotic products across home services, sports and wellness, and intelligent companionship. In 2025, OneRobotics recorded revenue of RMB 900 million, representing a year-on-year increase of 47.7%, with overseas revenue accounting for more than 95% of total revenue. The company has accumulated more than 3.6 million registered users globally and was officially included in the Southbound Stock Connect program in March 2026.For more information about OneModel, including detailed architecture analysis and benchmark results, please visit OneRobotics’ official website at http://www.onerobot.com/OneModel. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com